Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)

Wajeh Y. Qunibi, Robert E. Hootkins, Laveta L. McDowell, Micah S. Meyer, Matthias Simon, Rodolfo O. Garza, Russell W. Pelham, Mark V.B. Cleveland, Larry R. Muenz, David Y. He, Charles R Nolan Iii

Producción científica: Articlerevisión exhaustiva

200 Citas (Scopus)

Resumen

Background. Hyperphosphatemia underlies development of hyperparathyroidism, osteodystrophy, extraosseous calcification, and is associated with increased mortality in hemodialysis patients Methods. To determine whether calcium acetate or sevelamer hydrochloride best achieves recently recommended treatment goals of phosphorus ≤5.5 mg/dL and Ca x P product ≤55 mg2/dL 2, we conducted an 8-week randomized, double-blind study in 100 hemodialysis patients. Results. Comparisons of time-averaged concentrations (weeks 1 to 8) demonstrated that calcium acetate recipients had lower serum phosphorus (1.08 mg/dL difference, P = 0.0006), higher serum calcium (0.63 mg/dL difference, P < 0.0001), and lower Ca x P (6.1 mg2/dL2 difference, P = 0.022) than sevelamer recipients. At each week, calcium acetate recipients were 20% to 24% more likely to attain goal phosphorus [odds ratio (OR) 2.37, 95% CI 1.28-4.37, P = 0.0058], and 15% to 20% more likely to attain goal Ca x P (OR 2.16, 95% CI 1.20-3.86, P = 0.0097). Transient hypercalcemia occurred in 8 of 48 (16.7%) calcium acetate recipients, all of whom received concomitant intravenous vitamin D. By regression analysis hypercalcemia was more likely with calcium acetate (OR 6.1, 95% CI 2.8-13.3, P < 0.0001). Week 8 intact PTH levels were not significantly different. Serum bicarbonate levels were significantly lower with sevelamer hydrochloride treatment (P < 0.0001). Conclusion. Calcium acetate controls serum phosphorus and calcium-phosphate product more effectively than sevelamer hydrochloride. Cost-benefit analysis indicates that in the absence of hypercalcemia, calcium acetate should remain the treatment of choice for hyperphosphatemia in hemodialysis patients.

Idioma originalEnglish (US)
Páginas (desde-hasta)1914-1926
Número de páginas13
PublicaciónKidney international
Volumen65
N.º5
DOI
EstadoPublished - may 2004

ASJC Scopus subject areas

  • Nephrology

Huella

Profundice en los temas de investigación de 'Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study)'. En conjunto forman una huella única.

Citar esto